Table 5 Discussion and conclusions about planning further studies
From: Questions asked and answered in pilot and feasibility randomized controlled trials
| Â | Â | Drug (n = 28) | Non-drug (n = 22) | P |
|---|---|---|---|---|
Coverage of feasibility issues in the Discussion section | none | 8 (29%) | 3 (14%) | 0.0021 |
| Â | minimal | 9 (32%) | 2 (9%) | Â |
| Â | substantial | 9 (32%) | 7 (32%) | Â |
| Â | major focus of section | 2 (7%) | 10 (46%) | Â |
Extent of discussion or recommendations about planning future trials | none | 6 (21%) | 1 (5%) | 0.0021 |
| Â | minimal | 21 (75%) | 13 (59%) | Â |
| Â | substantial | 1 (5%) | 8 (36%) | Â |
| Â | major focus of section | 0 | 0 | Â |
One or more conclusion about methodological issues in a conclusions section | 7/14 (50%) | 16/18 (89%) | 0.0223 | |
One or more conclusion about methodological issues in the Abstract | 5 (18%) | 11 (50%) | 0.0313 | |
Conducting a subsequent trial or about to start one in the near future | 3 (11%) | 3 (14%) | 1.0003 | |